Trouton T G, Adgey A A
Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, N. Ireland.
Int J Cardiol. 1989 Apr;23(1):53-7. doi: 10.1016/0167-5273(89)90329-x.
Twenty patients with moderate or severe pain of suspected myocardial infarction received nalbuphine 50 mg intravenously as analgesia in 2 divided doses of 30 mg and 20 mg with 10 mg metoclopramide and were observed for 2 hours. Eighteen patients received nalbuphine outside hospital. The median time from onset of pain to treatment was 73 minutes. Within 30 minutes of the drug's administration 90% of all patients reported satisfactory pain relief (grade 0 or 1). For those with definite myocardial infarction 83% reported satisfactory pain relief at 30 minutes. There were no significant adverse cardiorespiratory effects observed or serious side-effects reported. Nalbuphine is effective and safe when used in this higher dose, although no additional analgesic effect was demonstrated when compared with lower established doses used early in acute myocardial infarction.
20例疑似心肌梗死伴中重度疼痛的患者静脉注射50毫克纳布啡进行镇痛，分两次给药，分别为30毫克和20毫克，并加用10毫克甲氧氯普胺，观察2小时。18例患者在院外接受纳布啡治疗。从疼痛发作到治疗的中位时间为73分钟。给药后30分钟内，90%的患者报告疼痛缓解满意（0级或1级）。对于确诊为心肌梗死的患者，83%在30分钟时报告疼痛缓解满意。未观察到明显的不良心肺效应，也未报告严重副作用。纳布啡以这种较高剂量使用时有效且安全，尽管与急性心肌梗死早期使用的较低既定剂量相比，未显示出额外的镇痛效果。
